AstraZeneca to Introduce Advanced Breast Cancer Medicine Datverzo in India in November
The pharmaceutical company confirmed the planned launch through a regulatory filing submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on November 7, 2026. The announcement follows the receipt of import and marketing permission from the Drugs Controller General of India (DCGI) in December 2025.